Diaceutics PLC announced that it has increased the number of enterprise-wide engagements it has with top 20 global pharma customers from four to six engagements, across 29 separate therapeutic brands. These enterprise-wide engagements demonstrate the successful execution of Diaceutics' strategy to offer more products & services to existing customers. An enterprise-wide engagement is characterized by a customer deploying the DXRX solutions across three or more of the precision medicines in its portfolio, or a customer deploying the DXRX solutions as the primary commercialization tool for a precision medicine.

In addition to the two new engagements announced 16 May 2024, Diaceutics' largest existing enterprise-wide customer recently extended the term of its enterprise-wide engagement through the end of 2026.